Search

Your search keyword '"Ponsioen, C. Y."' showing total 5 results
Start Over Author "Ponsioen, C. Y." Topic inflammatory bowel disease
5 results on '"Ponsioen, C. Y."'

1. Better survival of renal cell carcinoma in patients with inflammatory bowel disease

Author

Derikx, Lauranne A. A. P., Nissen, Loes H. C., Drenth, Joost P. H., van Herpen, Carla M., Kievit, Wietske, Verhoeven, Rob H. A., Mulders, Peter F. A., Hulsbergen-van de Kaa, Christina A., Boers-Sonderen, Marye J., van den Heuvel, Tim R. A., Pierik, Marieke, Nagtegaal, Iris D., Hoentjen, Frank, Kluin, P. M., Hogenes, M., Hamel, A. F., Natté, R., van Dijk, C. M., Kusters-Vandevelde, H. V. N., Sastrowijoto, S. H., Willig, A. P., Dijkstra, G., van der Meulen-de Jong, A. E., Vu, M. K., Cats, A., Haanen, J. B. A. G., van der Woude, C. J., Russel, M. G. V. M., Oldenburg, B., Meeuse, J. J., Corporaal, S., Zonneveld, A. M., Wahab, P. J., van den Hazel, S. J., Mares, W. G. N., Lieverse, R. J., Meijssen, M. A. C., Thuernau, K., Janik, D., van der Heide, H., Ponsioen, C. Y., Stokkers, P. C. F., Gastroenterology and Hepatology, Interne Geneeskunde, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
Male, Time Factors, Kaplan-Meier Estimate, urologic and male genital diseases, Inflammatory bowel disease, Crohn Disease, Risk Factors, Renal cell carcinoma, Odds Ratio, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Medicine, Registries, Early Detection of Cancer, Netherlands, Aged, 80 and over, education.field_of_study, Age Factors, Middle Aged, Prognosis, Kidney Neoplasms, female genital diseases and pregnancy complications, Oncology, Cohort, Female, medicine.symptom, Immunosuppressive Agents, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, renal cell carcinoma, Pancolitis, medicine.medical_specialty, Population, immunosuppressive therapy, Risk Assessment, Immunocompromised Host, Predictive Value of Tests, inflammatory bowel disease, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, education, Carcinoma, Renal Cell, Aged, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, Tumor Necrosis Factor-alpha, business.industry, Retrospective cohort study, Odds ratio, medicine.disease, digestive system diseases, Surgery, Cancer registry, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Multivariate Analysis, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Colitis, Ulcerative, Clinical Research Paper, business
Abstract

// Lauranne A.A.P. Derikx 1 , Loes H.C. Nissen 1 , Joost P.H. Drenth 1 , Carla M. van Herpen 2 , Wietske Kievit 3 , Rob H.A. Verhoeven 4 , Peter F.A. Mulders 5 , Christina A. Hulsbergen-van de Kaa 6 , Marye J. Boers-Sonderen 2 , Tim R.A. van den Heuvel 7 , Marieke Pierik 7 , Iris D. Nagtegaal 6 , Frank Hoentjen 1 , On behalf of the Dutch Initiative on Crohn and Colitis (ICC), PALGA group and IBD/RCC group 1 Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud university medical centre, Nijmegen, The Netherlands 2 Department of Medical Oncology, Radboud university medical centre, Nijmegen, The Netherlands 3 Radboud Institute for Health Sciences, Radboud university medical centre, Nijmegen, The Netherlands 4 Netherlands comprehensive cancer organization / Netherlands Cancer Registry, Utrecht, The Netherlands 5 Department of Urology, Radboud university medical centre, Nijmegen, The Netherlands 6 Department of Pathology, Radboud university medical centre, Nijmegen, The Netherlands 7 Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands Correspondence to: Lauranne A.A.P. Derikx, e-mail: Lauranne.Derikx@radboudumc.nl Keywords: inflammatory bowel disease, renal cell carcinoma, immunosuppressive therapy Received: June 30, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Background: Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). Cancer specific data regarding risk and outcome are scarce and data for renal cell carcinoma (RCC) are lacking. We aimed(1) to identify risk factors for RCC development in IBD patients (2) to compare RCC characteristics, outcome and survival between IBD patients and the general population. Methods: A PALGA (Dutch Pathology Registry) search was performed to establish a case group consisting of all IBD patients with incident RCC in The Netherlands (1991–2013). Cases were compared with two separate control groups: (A) with a population-based IBD cohort for identification of risk factors (B) with a RCC cohort from the general population to compare RCC characteristics and outcomes. Results: 180 IBD patients with RCC were identified. Pancolitis (OR 1.8–2.5), penetrating Crohn’s disease (OR 2.8), IBD related surgery (OR 3.7–4.5), male gender (OR 3.2–5.0) and older age at IBD onset (OR 1.0–1.1) were identified as independent risk factors for RCC development. IBD patients had a significantly lower age at RCC diagnosis ( p < 0.001), lower N-stage ( p = 0.025), lower M-stage ( p = 0.020) and underwent more frequently surgical treatment for RCC ( p < 0.001) compared to the general population. This translated into a better survival ( p = 0.026; HR 0.7) independent of immunosuppression. Conclusions: IBD patients with a complex phenotype are at increased risk to develop RCC. They are diagnosed with RCC at a younger age and at an earlier disease stage compared to the general population. This translates into a better survival independent of immunosuppressive or anti-TNFα therapy.

Published
2015

2. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis

Author

Beaudoin, Melissa, Goyette, Philippe, Goel, Gautam, Louis, E., Mansfield, J. C., Mathew, C. G., McGovern, D. P., Mitrovic, M., Montgomery, G. W., Mowat, C., Newman, W., Palmieri, O., Panés, J., Lagace, Caroline, Parkes, M., Phillips, A., Ponsioen, C. Y., Potocnik, U., Prescott, N. J., Proctor, D. D., Radford-Smith, G. L., Regueiro, M., Rioux, J. D., Roberts, R., Annese, Vito, Rotter, J. I., Rutgeerts, P., Sanderson, J., Sans, M., Satsangi, J., Schreiber, S., Schumm, P., Seibold, F., Sharma, Y., Silverberg, M. S., Bitton, Alain, Simms, L. A., Steinhart, A., Targan, S. R., Taylor, K. D., Torkvist, L., Vermeire, S., Halfvarson, J., Verspaget, H. W., De Vos, M., Walters, T., Begun, Jakob, Wang, K., Weersma, R. K., Whiteman, D., Wijmenga, C., Brant, Steven R., Bresso, Francesca, Cho, Judy H., Duerr, Richard H., Halfvarson, Jonas, Boucher, Gabrielle, McGovern, Dermot P. B., Radford-Smith, Graham, Schreiber, Stefan, Schumm, Philip L., Sharma, Yashoda, Silverberg, Mark S., Weersma, Rinse K., Quebec IBD Genetics Consortium, NIDDK IBD Genetics Consortium, International IBD Genetics Consortium (IIBDGC), Lo, Ken Sin, D'Amato, Mauro, Vermeire, Severine, Franke, Andre, Lettre, Guillaume, Xavier, Ramnik J., Daly, Mark J., Rioux, John D., Aumais, G., Bernard, E. J., Bitton, A., Rivas, Manuel A., Cohen, A., Deslandres, C., Lahaie, R., Paré, P., Brant, S. R., Cho, J. H., Duerr, R. H., Stevens, Christine, Ahmad, T., Anderson, C. A., Annese, V., Baldassano, R. N., Balschun, T., Barclay, M., Barrett, J. C., Bayless, T. M., Bis, J. C., Alikashani, Azadeh, Brand, S., Bumpstead, S., Buning, C., Colombel, J. F., Cottone, M., D'Amato, M., D'Inca, R., Ladouceur, Martin, Daly, M. J., Denson, T., Dubinsky, M., Edwards, C., Ellinghaus, D., Florin, T., Franchimont, D., Franke, A., Gearry, R., Ellinghaus, David, Georges, M., Glas, J., Van Gossum, A., Griffiths, A. M., Guthery, S. L., Hakonarson, H., Haritunians, T., Hugot, J. P., de Jong, D. J., Jostins, L., Torkvist, Leif, Kugathasan, S., Kullak-Ublick, G., Latiano, A., Laukens, D., Lawrance, I., Lee, J., Lees, C. W., Lemann, M., Levine, A., Libioulle, C., and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)

Subjects
Cancer Research, Génétique clinique, LIVER, Genome-wide association study, Inflammatory bowel disease, 0302 clinical medicine, Crohn Disease, GENETIC-VARIANTS, Medicine and Health Sciences, Ethnicity, UBIQUITIN LIGASES, Genetics(clinical), Genetics (clinical), Genetics, 0303 health sciences, Ecology, High-Throughput Nucleotide Sequencing, CROHN-DISEASE, CROHNS-DISEASE, 3. Good health, 030220 oncology & carcinogenesis, Medical genetics, Biologie, Research Article, EXPRESSION, medicine.medical_specialty, Canada, lcsh:QH426-470, SUSCEPTIBILITY LOCI, Evolution, Ubiquitin-Protein Ligases, Ethnic Groups, Evolution des espèces, Biology, Molecular gastro-enterology and hepatology Pathogenesis and modulation of inflammation [IGMD 2], Polymorphism, Single Nucleotide, 03 medical and health sciences, Behavior and Systematics, medicine, Humans, Genetic Predisposition to Disease, Ligase activity, MODULATION, Allele, GENOME-WIDE ASSOCIATION, Molecular Biology, Genotyping, Ecology, Evolution, Behavior and Systematics, 030304 developmental biology, Genetic association, Ecologie, Biologie moléculaire, Receptors, Interleukin, medicine.disease, NUCLEAR FACTOR 4-ALPHA, Genetic architecture, Cancérologie, CARD Signaling Adaptor Proteins, lcsh:Genetics, CELLS, Colitis, Ulcerative, INTESTINAL EPITHELIAL-CELLS, Genome-Wide Association Study, INFLAMMATORY-BOWEL-DISEASE
Abstract

Genome-wide association studies and follow-up meta-analyses in Crohn's disease (CD) and ulcerative colitis (UC) have recently identified 163 disease-associated loci that meet genome-wide significance for these two inflammatory bowel diseases (IBD). These discoveries have already had a tremendous impact on our understanding of the genetic architecture of these diseases and have directed functional studies that have revealed some of the biological functions that are important to IBD (e.g. autophagy). Nonetheless, these loci can only explain a small proportion of disease variance (~14% in CD and 7.5% in UC), suggesting that not only are additional loci to be found but that the known loci may contain high effect rare risk variants that have gone undetected by GWAS. To test this, we have used a targeted sequencing approach in 200 UC cases and 150 healthy controls (HC), all of French Canadian descent, to study 55 genes in regions associated with UC. We performed follow-up genotyping of 42 rare non-synonymous variants in independent case-control cohorts (totaling 14,435 UC cases and 20,204 HC). Our results confirmed significant association to rare non-synonymous coding variants in both IL23R and CARD9, previously identified from sequencing of CD loci, as well as identified a novel association in RNF186. With the exception of CARD9 (OR = 0.39), the rare non-synonymous variants identified were of moderate effect (OR = 1.49 for RNF186 and OR = 0.79 for IL23R). RNF186 encodes a protein with a RING domain having predicted E3 ubiquitin-protein ligase activity and two transmembrane domains. Importantly, the disease-coding variant is located in the ubiquitin ligase domain. Finally, our results suggest that rare variants in genes identified by genome-wide association in UC are unlikely to contribute significantly to the overall variance for the disease. Rather, these are expected to help focus functional studies of the corresponding disease loci. © 2013 Beaudoin et al., 0, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013
Full Text
View/download PDF

3. Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Author

Severs, M., van Erp, S. J. H., van der Valk, M. E., Mangen, M. J. J., Fidder, H. H., van der Have, M., van Bodegraven, A. A., de Jong, D. J., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H. M., Jansen, J. M., van de Meeberg, P. C., Mahmmod, N., Ponsioen, C. Y., Bolwerk, C., Vermeijden, J. R., Pierik, M. J., Siersema, P. D., and Leenders, M.

Abstract

Background and aims: Smoking affects the course of disease in patients with ulcerative colitis (UC) and Crohn's disease (CD). We aimed to study the association between smoking and extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). Methods: We cross-sectionally explored the association between smoking and EIMs in IBD in three cohort studies: (1) the COIN study, designed to estimate healthcare expenditures in IBD; (2) the Groningen study, focused on cigarette smoke exposure and disease behaviour in IBD; and (3) the JOINT study, evaluating joint and back manifestations in IBD. Results: In the COIN, Groningen and JOINT cohorts, 3030, 797 and 225 patients were enrolled, of whom 16, 24 and 23.5% were current smokers, respectively. Chronic skin disorders and joint manifestations were more prevalent in smoking IBD patients than in non-smokers (COIN, 39.1 vs 29.8%, p <0.01; Groningen, 41.7 vs 30.0%, p <0.01) in both CD and UC. In the JOINT cohort, smoking was more prevalent in IBD patients with joint manifestations than in those without (30.3 vs 13.0%, p <0.01). EIMs appeared to be more prevalent in high- than in low-exposure smokers (56.0 vs 37.1%, p = 0.10). After smoking cessation, the prevalence of EIMs in IBD patients rapidly decreased towards levels found in never smokers (lag time: COIN cohort, 1-2 years; Groningen cohort, within 1 year). Conclusions: There is a robust dose-dependent association between active smoking and EIMs in both CD and UC patients. Smoking cessation was found to result in a rapid reduction of EIM prevalence to levels encountered in never smokers. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

4. Early reconstruction of the leaking ileal pouch-anal anastomosis: a novel solution to an old problem.

Author

Gardenbroek, T. J., Musters, G. D., Buskens, C. J., Ponsioen, C. Y., D'Haens, G. R. A. M., Dijkgraaf, M. G. W., Tanis, P. J., and Bemelman, W. A.

Subjects
SURGICAL anastomosis, ONCOLOGIC surgery, CANCER patients, SURGICAL complications, ONCOLOGY
Abstract

Aim The study aimed to determine the effectiveness and direct medical costs of early surgical closure of the anastomotic defect after a short course of Endo-sponge® therapy of the presacral cavity, compared with conventional treatment in patients with anastomotic leakage after ileal pouch-anal anastomosis ( IPAA). Method Patients with anastomotic leakage after IPAA undergoing early surgical closure of the anastomotic defect after a short Endo-sponge® treatment were prospectively followed and compared with a consecutive cohort of patients with an anastomotic leak treated by creation of a loop ileostomy and occasional drainage of the presacral cavity. Results A total of 15 patients were treated with early surgical closure and 29 were treated conventionally. In the early surgical closure group, the Endo-sponge® treatment was continued for a median of 12 days [interquartile range ( IQR) 7-15 days] with a median of 3 ( IQR 2-4) Endo-sponge® changes. Secondary anastomotic healing was achieved in all patients ( n = 15) in the early surgical closure group compared with 52% ( n = 16) in the conventional treatment group ( P = 0.003). Closure of the anastomotic defect was achieved after a median of 48 (25-103) days in the early surgical closure group compared with 70 ( IQR 49-175) days in the conventional treatment group ( P = 0.013). A functional pouch was seen in 93% and 86% of the patients in each group. There was no significant difference in direct medical cost. Conclusion Early surgical closure after a short period of Endo-sponge® treatment is highly effective in treating anastomotic leakage after IPAA without increasing cost. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

5. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis.

Author

Bartels, S. A. L., Gardenbroek, T. J., Bos, L., Ponsioen, C. Y., D'Haens, G. R. A. M., Tanis, P. J., Buskens, C. J., and Bemelman, W. A.

Subjects
COLITIS, PREOPERATIVE care, COLECTOMY, INFLAMMATORY bowel diseases, COLON surgery, HOSPITAL admission & discharge, PATIENTS
Abstract

Aim Risk factors for postoperative complications in patients undergoing emergency colectomy for severe colitis in inflammatory bowel disease have hardly been studied. Therefore, this study aimed to define predictors of a complicated postoperative course in these patients. Method A retrospective review was performed of 71 consecutive patients who underwent emergency colectomy for severe colitis between 1999 and 2012 at a tertiary referral centre. Complications were graded according to the Clavien-Dindo classification. Patients with a complication Grade II or higher were compared with those with no complications or a Grade I complication. Results Nineteen patients (26.7%) had at least one postoperative complication classified as Clavien-Dindo Grade II or higher. In the group with postoperative complications, patients had a higher age (mean 45 vs 35 years, P = 0.020) and a higher body mass index ( BMI) (mean 25.9 vs 21.0 kg/m2, P = 0.006). Length of preoperative hospital stay (median 15 vs 6 days, P = 0.032) was longer in the group with postoperative complications. During the study period, the preoperative hospital stay decreased by 0.8 days per study year (95% CI 0.2-1.5 days, P < 0.001). This did not influence the complication rate over time, however. Conclusion Factors increasing the risk of complications after emergency colectomy for severe colitis were a higher age, a higher BMI and a longer preoperative hospital stay. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results